One stock that might be an intriguing choice for investors right now is AnaptysBio, Inc. ANAB. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate...
Wednesday’s drop pushed AnaptysBio stock to its lowest closing level since December 2023, intensifying concerns among retail investors.
AnaptysBio halts ANB032 investment after ineffective trial results; focuses on other assets, with cash runway through 2027.Quiver AI SummaryAnaptysBio, Inc. announced that its investigational drug ANB032,...
The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.
A powerfully bullish new analyst take on the company helped it rally on the market.
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.